NASDAQ:BMEA

Biomea Fusion Stock Insider Trading

Healthcare > Biotechnology

Buy BMEA

*Your capital is at risk

$1.30

-0.0700 (-5.11%)

At Close: Jun 03, 2026

Biomea Fusion Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.44M and sold 307K BMEA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	10.44M shares
● Sell	307K shares
82% Buy Activity Moderate Positive Correlation
Buy Signal High Confidence Apr 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 29, 2023 Sell	Common Stock G-Gift	Erdtmann Rainer M President And COO	CEO / President	3 000 Value: $0
Dec 29, 2023 Sell	Common Stock G-Gift	Erdtmann Rainer M President And COO	CEO / President	3 000 Value: $0
Dec 29, 2023 Sell	Common Stock G-Gift	Erdtmann Rainer M President And COO	CEO / President	12 000 Value: $0
Dec 29, 2023 Buy	Common Stock G-Gift	Erdtmann Rainer M President And COO	CEO / President	3 000 Value: $0
Dec 29, 2023 Buy	Common Stock G-Gift	Erdtmann Rainer M President And COO	CEO / President	3 000 Value: $0
Nov 30, 2023 Buy	Common Stock A-Award	Valle Franco Chief Financial Officer	C-Suite Officer	1 345 Value: $5K
Nov 30, 2023 Buy	Common Stock A-Award	Valle Franco Chief Financial Officer	C-Suite Officer	1 345 Value: $5K
Aug 31, 2023 Buy	Common Stock J-Other	Frias Juan Pablo Insider	Other	0 Value: $0
Aug 31, 2023 Buy	Stock Option (Right to Buy) A-Award	Frias Juan Pablo Chief Medical Officer	Officer	300 000 Value: $5.06M
Aug 31, 2023 Buy	Stock Option (Right to Buy) A-Award	Frias Juan Pablo Chief Medical Officer	Officer	300 000 Value: $5.06M
Aug 31, 2023 Buy	Common Stock J-Other	Frias Juan Pablo Insider	Other	0 Value: $0
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Faust Elizabeth Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Hitchcock Michael J.m. Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (right to buy) A-Award	Chen Bihua	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Faust Elizabeth Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Ray Sumita Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Aguiar Eric Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Aguiar Eric Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Ray Sumita Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (Right to Buy) A-Award	Hitchcock Michael J.m. Director	Director	6 989 Value: $271.9K
Jun 14, 2023 Buy	Stock Option (right to buy) A-Award	Chen Bihua	Director	6 989 Value: $271.9K
Jun 01, 2023 Sell	Common Stock S-Sale	A2a Pharmaceuticals, Inc. 10 Percent Owner	10% Owner	50 000 Value: $1.73M
May 31, 2023 Buy	Common Stock A-Award	Valle Franco Chief Financial Officer	C-Suite Officer	4 273 Value: $16.2K
May 31, 2023 Buy	Common Stock A-Award	Valle Franco Chief Financial Officer	C-Suite Officer	4 273 Value: $16.2K
May 31, 2023 Sell	Common Stock S-Sale	A2a Pharmaceuticals, Inc. 10 Percent Owner	10% Owner	75 000 Value: $2.54M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOMEA FUSION, INC.

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in R...

Read Full Profile Here